Baricitinib is a small molecule inhibitor that targets Janus kinase (JAK) enzymes. It is primarily approved for the treatment of rheumatoid arthritis but has garnered interest in oncology due to its potential to modulate immune responses and inhibit pathways involved in cancer progression.
